AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$MGX

Irish Jian sold $2K of MGX

Irish Jian (See Remarks) sold 2,140 shares of Metagenomi Therapeutics, Inc. (MGX) at $1.16 on 2026-09-08.

Original reporting
SEC EDGAR · Irish Jian
Published Sep 10, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 7:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MGX
Bearish
high confidence
Mentioned
$MGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGXBearishLow
01

Why it matters

The sale is minor and does not alter control; price impact likely negligible.

02

Market read

Routine insider sale with minimal market relevance.

03

What to watch

Potential upcoming dilution or financing events not disclosed.

Relevance 3/10Novelty 3/10Timing: filed 2026-09-10

Background

Form 4 filings disclose insider transactions; traders watch for material changes in holdings.

Company-level read

Ticker impact

$MGXBearishHigh confidence
Context

Officer Irish Jian sold 2,140 shares of MGX for $2,479, a routine insider sale under $1M.

Expected impact

No significant price change expected.

Evidence & confidence

Sale size is trivial relative to market cap; insider remains a large holder.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market impact negligible.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor for further disposals.

Key entities

  • Company
    Metagenomi Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker MGX.

  • Insider
    Irish Jian

    Officer and director of MGX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MGX insider trading history →

Related articles

AUG 10
$MGXMed

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in

SEC EDGAR 8-K4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min